title: [Fixed-dose combination].
abstract: Many patients with type 2 diabetes mellitus(T2DM) do not achieve satisfactory glycemic control by monotherapy alone, and often require multiple oral hypoglycemic agents (OHAs). Combining OHAs with complementary mechanisms of action is fundamental to the management of T2DM. Fixed-dose combination therapy(FDC) offers a method of simplifying complex regimens. Efficacy and tolerability appear to be similar between FDC and treatment with individual agents. In addition, FDC can enhance adherence and improved adherence may result in improved glycemic control. Four FDC agents are available in Japan: pioglitazone-glimepiride, pioglitazone-metformin, pioglitazone-alogliptin, and voglibose-mitiglinide. In this review, the advantages and disadvantages of these four combinations are identified and discussed.
authors: Yoshio
authors: Y
authors: Nagai
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007294:Inositol / Q000008:administration & dosage / Q000031:analogs & derivatives; D054833:Isoindoles / Q000008:administration & dosage; D008687:Metformin / Q000008:administration & dosage; D000077205:Pioglitazone; D010880:Piperidines / Q000008:administration & dosage; D013453:Sulfonylurea Compounds / Q000008:administration & dosage; D045162:Thiazolidinediones / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D007004:Hypoglycemic Agents; D054833:Isoindoles; D010880:Piperidines; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D007294:Inositol; D014498:Uracil; C057619:glimepiride; D008687:Metformin; C087255:mitiglinide; C520853:alogliptin; C102817:voglibose; D000077205:Pioglitazone